Pharm

Alirocumab

search

Alirocumab, Praluent

  • See Also
  1. PCSK9 Inhibitor
  2. AntiHyperlipidemic
  3. Hyperlipidemia Management
  4. Evolocumab
  5. Inclisiran (Leqvio)
  • Mechanism
  1. See PCSK9 Inhibitor
  2. Human Monoclonal Antibody (PCSK9 Inhibitor)
  • Indications
  1. Severe familial Hypercholesterolemia (e.g. LDL Cholesterol >190 mg/dl)
  • Dosing
  1. Store in refrigerator at 36 to 46 degrees
    1. May also store in original carton up to 30 days at room Temperature <77 F
  2. Administer subcutaneously in the Abdomen, back of the upper arm or the thigh
    1. Warm to room Temperature for 30 to 40 minutes before use
    2. Administration of full dose may require 10 to 20 seconds
  3. Start 75 mg SC every 2 weeks
  4. Maximum
    1. Every 2 weeks: 150 mg SC
    2. Every 4 weeks: 300 mg SC (2 doses injected at different sites)
  • Efficacy
  1. See PCSK9 Inhibitor
  2. Lower LDL Cholesterol up to 45 to 48% when added to a Statin
  • Disadvantages
  1. See PCSK9 Inhibitor
  2. Costs $450 per 2 weeks (>$10,000 per year) in 2022
  • Safety
  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation
  • Resources
  1. Alirocumab (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4
  • References
  1. (2015) Presc Lett 22(9): 50-1
  2. Hamilton (2020) Tarascon Pocket Pharmacopoeia
  3. (2022) Non-StatinLipid Lowering Agents, Presc Lett, #380202
  4. (2022) Med Lett Drug Ther 64(1659): 145-52
  5. Robinson (2015) N Engl J Med 372(16):1489-99 +PMID:25773378 [PubMed]
  6. Stroes (2014) J Am Coll Cardiol 63(23):2541-8 [PubMed]